+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

  • PDF Icon

    Report

  • 180 Pages
  • August 2023
  • Region: United States
  • Renub Research
  • ID: 5562701
United States Pain Management Therapeutics Market is expected to reach US$ 33.71 Billion by 2030, according to the report. Physical and mental pain has a significant influence on life. It can hinder our daily activities, limit our mobility, and dampen our spirits. Advancements in medical technology and growing awareness have opened up new possibilities in pain management. Medications have traditionally been frequently used in pain treatment to ease or suppress discomfort caused by a variety of disorders. Recognizing the need for new ways, the healthcare sector has focused on the development of pain monitoring devices.

Pain monitoring devices offer a non-invasive and objective means of assessing an individual's pain experience. By providing healthcare professionals with quantitative data, these devices enable personalized treatment plans and help optimize the effectiveness of pain management strategies. Individuals are becoming more aware of the advantages of pain management devices, especially when compared to opioids, which is boosting demand for these novel solutions. The pharmaceutical industry expansion and innovation in the production of pain-relieving drugs creates potential for the US pain management medication market. Factors such as an increase in pain disorders, improved healthcare infrastructure, and demand for safer and more effective pain drugs are driving market growth. The rising number of health-conscious customers, as well as the incidence of chronic illnesses among the elderly, contributes to the market expansion.

United States Pain Management Therapeutics Market will register a CAGR of 3.65% from 2022 to 2030

Elderly individuals, who often experience chronic pain due to joint disorders and various surgeries, require prescribed pain medications, further driving the growth of the U.S. pain management drug market. The rise in cases of diabetic neuropathies, which lead to pain, also contributes to the market expansion. Educational efforts by various organizations and the government regarding pain disorders and proper pain management play a significant role in raising awareness. With the introduction of e-commerce, companies have gained a vital tool that allows customers to conveniently access products and services.

In the context of pain management, health apps and online platforms provide animations and educational resources to inform people about the appropriate dosages and frequencies of pain medications, thereby contributing to the growth of the U.S. pain management drug market. Increased promotional activities by manufacturers and growing awareness among the general population about the proper treatment of pain disorders are expected to fuel the adoption of pain management medications in the future. The area of pain treatment is changing, and the incorporation of new technology and pharmaceuticals offers enormous potential for improving the lives of those who are in pain. The future of pain treatment is brighter, with a focus on personalized methods and a shift away from opioids, bringing hope for a better quality of life for people in need. The United States Pain Management Therapeutics Market was valued at US$ 25.31 Billion in 2022.

United States, pharmaceutical organization performs substantial research, development, and marketing of pain management medications

By Therapeutics, the United States Pain Management Therapeutics Market is segmented into Pharmaceuticals and Devices. The United States pharmaceutical Pain Management Therapeutics Market is a dynamic and rapidly evolving sector within the healthcare industry. As the population ages and chronic pain becomes increasingly common, the demand for effective pain management methods grows. In recent years, there has been a shift in attention toward developing unique and targeted pain management drugs that give more pain relief while lowering the risk of addiction and harmful side effects. As a result, new pharmaceutical items and therapies have entered the market. Advancements in technology and understanding of pain mechanisms drive innovation, such as targeted therapies, precision medicine, and alternative options like medical cannabis. The market is dynamic, aiming to meet the growing demand for effective pain relief. Advancing medications, technology, and treatments holds promise for enhancing the lives of individuals in pain.

Neurostimulation has emerged as the fastest-growing segment in the U.S. pain management drug market

By Devices, the United States Pain Management Therapeutics Market is divided into Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion pumps, and Neurostimulation. Neurostimulation is rapidly gaining momentum in the U.S. pain management drug market. With its implanted devices delivering electrical impulses to nerves, it offers targeted relief for chronic pain conditions. Its effectiveness in reducing pain and improving quality of life has fueled its growth. The market for neurostimulation devices is increasing because they provide a viable alternative to traditional pain drugs, answering the need in the United States for safer and more tailored pain treatment options.

Opioids hold the largest share of the United States pain management drug market

By Drug Class, the United States Pain Management Therapeutics Market is classified into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, opiates, and Non-narcotic Analgesics. While opioids are excellent pain relievers, their increasing usage has generated concerns owing to the potential of addiction and other negative side effects. Efforts are being undertaken to address these difficulties through the implementation of tougher restrictions, the promotion of responsible prescription practices, and the investigation of alternative pain management choices. In order to achieve a balance between effective pain relief and reducing the risks associated with opioid use, the market is changing toward safer and more customized medications, as well as non-pharmacological alternatives.

Cancer pain is experiencing rapid growth within the U.S. pain management drug market

The Pain Management Therapeutics Market in the United States is classified as Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-operative Pain, Migraine, Fibromyalgia, Bone fracture, Muscle sprain or strain, acute appendicitis, and others. With the increased prevalence of cancer cases, there is a greater need for cancer patients to be treated effectively in terms of pain management. Cancer pain management requires a multimodal approach that includes pharmaceutical medicines like opioids and adjuvant medications, as well as non-pharmacological techniques like radiation therapy and nerve blocks. The emphasis is on promoting patient comfort and minimizing the impact of pain on everyday activities. Innovative medicines and pharmaceuticals are being developed to address this crucial part of cancer care as awareness and research in cancer pain management continue to grow.

Chronic pain holds the highest market share and is the fastest-growing segment in the U.S. pain management drug market

By Pain Type, the United States Pain Management Therapeutics Market is subdivided into Chronic Pain and Acute Pain. The powerful medications are commonly prescribed for severe acute and chronic pain. With a substantial number of individuals suffering from persistent pain conditions, there is a pressing need for effective management options. The market offers a wide range of pharmaceutical treatments, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and antidepressants, tailored to address different types of chronic pain. Additionally, advancements in technology, such as neurostimulation and targeted therapies, are reshaping the landscape of chronic pain management, providing individuals with new hope for alleviating their pain and improving their quality of life.

Online pharmacy market boasts the highest market share and is the fastest-growing segment in the U.S. pain management drug industry

By Distribution Channel, the United States Pain Management Therapeutics Market is broken up into Hospital Pharmacies, Retail pharmacies, and Online Pharmacies. With the convenience and accessibility of online platforms, individuals are increasingly turning to online pharmacies to fulfill their medication needs. Online pharmacies provide a wide choice of pain management pharmaceuticals, allowing people to get pain relief treatments without having to go to a regular pharmacy. The rising popularity of online shopping, along with rising demand for pain management pharmaceuticals, has contributed to the spectacular rise of the online pharmacy business in the US pain management sector.

Key Players

Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson, and Baxter International Inc. are prominent players in the pain management industry, as highlighted in our analysis. This includes investing in technology innovation to develop advanced pain management solutions, forming partnerships to leverage complementary expertise, expanding their presence in different regions, and engaging in mergers and acquisitions to broaden their product portfolios and market reach.

This latest report “US Pain Management Therapeutics Industry, Forecast By Therapeutics (Pharmaceuticals, Devices), Devices (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pumps, Neurostimulation), Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-Migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis and Others), Pain Type (Chronic Pain, Acute Pain), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Companies (Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson and Baxter International Inc)” provides a detailed analysis of US Pain Management Therapeutics Industry.

Therapeutics - Market has been covered from 2 viewpoints:

1. Pharmaceuticals
2. Devices

Devices - Market has been covered from 4 viewpoints:

1. Electrical Stimulators
2. Radiofrequency Ablation
3. Analgesic Infusion Pumps
4. Neurostimulation

Drug Class - Market has been covered from 7 viewpoints:

1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2. Anesthetics
3. Anticonvulsants
4. Anti-Migraine Agents
5. Antidepressants
6. Opioids
7. Nonnarcotic Analgesics

Indication - Market has been covered from 11 viewpoints:

1. Arthritic Pain
2. Neuropathic Pain
3. Cancer Pain
4. Chronic Back Pain
5. Post-Operative Pain
6. Migraine
7. Fibromyalgia
8. Bone Fracture
9. Muscle Sprain/Strain
10. Acute Appendicitis
11. Others

Distribution Channel - Market has been covered from 3 viewpoints:

1. Hospital Pharmacies
2. Retail Pharmacies
3. Online Pharmacies

Pain Type - Market has been covered from 2 viewpoints:

1. Chronic Pain
2. Acute Pain

Company Insights:

  • Overview
  • Recent Development
  • Financial Insight

Companies Covered:

1. Eli Lilly and Company
2. Pfizer Inc.
3. GlaxoSmithKline plc
4. Novartis International AG
5. Merck & Co., Inc.
6. Abbott Laboratories
7. Johnson & Johnson
8. Baxter International Inc.

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Pain Management Therapeutics Market
6. Market Share - United States Pain Management Therapeutics Market
6.1 By Therapeutics
6.1.1 By Devices
6.2 By Drug Class
6.3 By Indication
6.4 By Pain Type
6.5 By Distribution Channel
7. Therapeutics - United States Pain Management Therapeutics Market
7.1 Pharmaceuticals
7.2 Devices
7.2.1 Electrical Stimulators
7.2.2 Radiofrequency Ablation
7.2.3 Analgesic Infusion Pumps
7.2.4 Neurostimulation
8. Drug Class - United States Pain Management Therapeutics Market
8.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8.2 Anesthetics
8.3 Anticonvulsants
8.4 Anti-Migraine Agents
8.5 Antidepressants
8.6 Opioids
8.7 Non-Narcotic Analgesics
9. Indication - United States Pain Management Therapeutics Market
9.1 Arthritic Pain
9.2 Neuropathic Pain
9.3 Cancer Pain
9.4 Chronic Back Pain
9.5 Post-Operative Pain
9.6 Migraine
9.7 Fibromyalgia
9.8 Bone Fracture
9.9 Muscle Sprain/Strain
9.10 Acute Appendicitis
9.11 Others
10. Pain Type - United States Pain Management Therapeutics Market
10.1 Chronic Pain
10.2 Acute Pain
11. Distribution Channel - United States Pain Management Therapeutics Market
11.1 Hospital Pharmacies
11.2 Retail Pharmacies
11.3 Online Pharmacies
12. Porter's Five Forces Analysis - United States Pain Management Therapeutics Market
12.1 Threat of New Entry
12.2 The Bargaining Power of Buyer
12.3 Threat of Substitution
12.4 The Bargaining Power of Supplier
12.5 Competitive Rivalry
13. SWOT Analysis - United States Pain Management Therapeutics Market
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat
14. Key Players Analysis
14.1 Eli Lilly and Company
14.1.1 Overview
14.1.2 Recent Development
14.1.3 SWOT Analysis
14.1.4 Financial Insight
14.2 Pfizer Inc.
14.2.1 Overview
14.2.2 Recent Development
14.2.3 SWOT Analysis
14.2.4 Financial Insight
14.3 GlaxoSmithKline plc
14.3.1 Overview
14.3.2 Recent Development
14.3.3 SWOT Analysis
14.3.4 Financial Insight
14.4 Novartis International AG
14.4.1 Overview
14.4.2 Recent Development
14.4.3 SWOT Analysis
14.4.4 Financial Insight
14.5 Merck & Co., Inc.
14.5.1 Overview
14.5.2 Recent Development
14.5.3 SWOT Analysis
14.5.4 Financial Insight
14.6 Abbott Laboratories
14.6.1 Overview
14.6.2 Recent Development
14.6.3 SWOT Analysis
14.6.4 Financial Insight
14.7 Johnson & Johnson
14.7.1 Overview
14.7.2 Recent Development
14.7.3 SWOT Analysis
14.7.4 Financial Insight
14.8 Baxter International Inc.
14.8.1 Overview
14.8.2 Recent Development
14.8.3 SWOT Analysis
14.8.4 Financial Insight
List of Figures
Figure 01: United States - Pain Management Therapeutics Market (Billion US$), 2018 - 2022
Figure 02: United States - Forecast for Pain Management Therapeutics Market (Billion US$), 2023 - 2030
Figure 03: Therapeutics - Pharmaceuticals Market (Billion US$), 2018 - 2022
Figure 04: Therapeutics - Forecast for Pharmaceuticals Market (Billion US$), 2023 - 2030
Figure 05: Therapeutics - Devices Market (Billion US$), 2018 - 2022
Figure 06: Therapeutics - Forecast for Devices Market (Billion US$), 2023 - 2030
Figure 07: Devices - Electrical Stimulators Market (Million US$), 2018 - 2022
Figure 08: Devices - Forecast for Electrical Stimulators Market (Million US$), 2023 - 2030
Figure 09: Devices - Radiofrequency Ablation Market (Million US$), 2018 - 2022
Figure 10: Devices - Forecast for Radiofrequency Ablation Market (Million US$), 2023 - 2030
Figure 11: Devices - Analgesic Infusion Pumps Market (Million US$), 2018 - 2022
Figure 12: Devices - Forecast for Analgesic Infusion Pumps Market (Million US$), 2023 - 2030
Figure 13: Devices - Neurostimulation Market (Million US$), 2018 - 2022
Figure 14: Devices - Forecast for Neurostimulation Market (Million US$), 2023 - 2030
Figure 15: Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (Billion US$), 2018 - 2022
Figure 16: Drug Class - Forecast for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (Billion US$), 2023 - 2030
Figure 17: Drug Class - Anesthetics Market (Billion US$), 2018 - 2022
Figure 18: Drug Class - Forecast for Anesthetics Market (Billion US$), 2023 - 2030
Figure 19: Drug Class - Anticonvulsants Market (Billion US$), 2018 - 2022
Figure 20: Drug Class - Forecast for Anticonvulsants Market (Billion US$), 2023 - 2030
Figure 21: Drug Class - Anti-Migraine Agents Market (Billion US$), 2018 - 2022
Figure 22: Drug Class - Forecast for Anti-Migraine Agents Market (Billion US$), 2023 - 2030
Figure 23: Drug Class - Antidepressants Market (Billion US$), 2018 - 2022
Figure 24: Drug Class - Forecast for Antidepressants Market (Billion US$), 2023 - 2030
Figure 25: Drug Class - Opioids Market (Billion US$), 2018 - 2022
Figure 26: Drug Class - Forecast for Opioids Market (Billion US$), 2023 - 2030
Figure 27: Drug Class - Non-Narcotic Analgesics Market (Billion US$), 2018 - 2022
Figure 28: Drug Class - Forecast for Non-Narcotic Analgesics Market (Billion US$), 2023 - 2030
Figure 29: Indication - Arthritic Pain Market (Billion US$), 2018 - 2022
Figure 30: Indication - Forecast for Arthritic Pain Market (Billion US$), 2023 - 2030
Figure 31: Indication - Neuropathic Pain Market (Billion US$), 2018 - 2022
Figure 32: Indication - Forecast for Neuropathic Pain Market (Billion US$), 2023 - 2030
Figure 33: Indication - Cancer Pain Market (Billion US$), 2018 - 2022
Figure 34: Indication - Forecast for Cancer Pain Market (Billion US$), 2023 - 2030
Figure 35: Indication - Chronic Back Pain Market (Billion US$), 2018 - 2022
Figure 36: Indication - Forecast for Chronic Back Pain Market (Billion US$), 2023 - 2030
Figure 37: Indication - Post-Operative Pain Market (Billion US$), 2018 - 2022
Figure 38: Indication - Forecast for Post-Operative Pain Market (Billion US$), 2023 - 2030
Figure 39: Indication - Migraine Market (Billion US$), 2018 - 2022
Figure 40: Indication - Forecast for Migraine Market (Billion US$), 2023 - 2030
Figure 41: Indication - Fibromyalgia Market (Billion US$), 2018 - 2022
Figure 42: Indication - Forecast for Fibromyalgia Market (Billion US$), 2023 - 2030
Figure 43: Indication - Bone Fracture Market (Million US$), 2018 - 2022
Figure 44: Indication - Forecast for Bone Fracture Market (Million US$), 2023 - 2030
Figure 45: Indication - Muscle Sprain/Strain Market (Million US$), 2018 - 2022
Figure 46: Indication - Forecast for Muscle Sprain/Strain Market (Million US$), 2023 - 2030
Figure 47: Indication - Acute Appendicitis Market (Million US$), 2018 - 2022
Figure 48: Indication - Forecast for Acute Appendicitis Market (Million US$), 2023 - 2030
Figure 49: Indication - Others Market (Million US$), 2018 - 2022
Figure 50: Indication - Forecast for Others Market (Million US$), 2023 - 2030
Figure 51: Pain Type - Chronic Pain Market (Billion US$), 2018 - 2022
Figure 52: Pain Type - Forecast for Chronic Pain Market (Billion US$), 2023 - 2030
Figure 53: Pain Type - Acute Pain Market (Million US$), 2018 - 2022
Figure 54: Pain Type - Forecast for Acute Pain Market (Million US$), 2023 - 2030
Figure 55: Pain Type - Hospital Pharmacies Market (Billion US$), 2018 - 2022
Figure 56: Pain Type - Forecast for Hospital Pharmacies Market (Billion US$), 2023 - 2030
Figure 57: Pain Type - Retail Pharmacies Market (Billion US$), 2018 - 2022
Figure 58: Pain Type - Forecast for Retail Pharmacies Market (Billion US$), 2023 - 2030
Figure 59: Pain Type - Online Pharmacies Market (Billion US$), 2018 - 2022
Figure 60: Pain Type - Forecast for Online Pharmacies Market (Billion US$), 2023 - 2030
Figure 61: Eli Lilly and Company - Global Revenue (Billion US$), 2018 - 2022
Figure 62: Eli Lilly and Company - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 63: Pfizer Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 64: Pfizer Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 65: GlaxoSmithKline plc - Global Revenue (Billion US$), 2018 - 2022
Figure 66: GlaxoSmithKline plc - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 67: Novartis International AG - Global Revenue (Billion US$), 2018 - 2022
Figure 68: Novartis International AG - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 69: Merck & Co., Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 70: Merck & Co., Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 71: Abbott Laboratories - Global Revenue (Billion US$), 2018 - 2022
Figure 72: Abbott Laboratories - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 73: Johnson & Johnson - Global Revenue (Billion US$), 2018 - 2022
Figure 74: Johnson & Johnson - Forecast for Global Revenue (Billion US$), 2023 - 2030
Figure 75: Boehringer Ingelheim - Global Revenue (Billion US$), 2018 - 2022
Figure 76: Boehringer Ingelheim - Forecast for Global Revenue (Billion US$), 2023 - 2030
List of Tables
Table 01: United States - Pain Management Therapeutics Market Share by Therapeutics (Percent), 2018 - 2022
Table 02: United States - Forecast for Pain Management Therapeutics Market Share by Therapeutics (Percent), 2023 - 2030
Table 03: United States - Pain Management Therapeutics Market Share by Devices (Percent), 2018 - 2022
Table 04: United States - Forecast for Pain Management Therapeutics Market Share by Devices (Percent), 2023 - 2030
Table 05: United States - Pain Management Therapeutics Market Share by Drug Class (Percent), 2018 - 2022
Table 06: United States - Forecast for Pain Management Therapeutics Market Share by Drug Class (Percent), 2023 - 2030
Table 07: United States - Pain Management Therapeutics Market Share by Indication (Percent), 2018 - 2022
Table 08: United States - Forecast for Pain Management Therapeutics Market Share by Indication (Percent), 2023 - 2030
Table 09: United States - Pain Management Therapeutics Market Share by Pain Type (Percent), 2018 - 2022
Table 10: United States - Forecast for Pain Management Therapeutics Market Share by Pain Type (Percent), 2023 - 2030
Table 11: United States - Pain Management Therapeutics Market Share by Distribution Channel (Percent), 2018 - 2022
Table 12: United States - Forecast for Pain Management Therapeutics Market Share by Distribution Channel (Percent), 2023 - 2030

Companies Mentioned

  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Merck & Co., Inc.
  • Abbott Laboratories
  • Johnson & Johnson
  • Baxter International Inc.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information